SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917063498> ?p ?o ?g. }

Showing items 1 to 100 of ±194 with 100 items per page.

W2917063498 endingPage "129" @default.
W2917063498 startingPage "115" @default.
W2917063498 abstract "•Role of 18FDG-PET in diagnosis (T), staging (N/M) and relapse of BTC was assessed. •18FDG-PET is not recommended for diagnosis (T) in the absence of cytology/histology. •18FDG-PET should be incorporated into current guidelines for staging (N/M) and relapse. •18FDG-PET should be used for staging (N/M) if identification of occult sites of disease will alter management. •18FDG-PET should be used to identify relapse if suspicion remains following standard imaging. Background & Aims The role of 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and staging of patients with biliary tract cancers (BTCs) remains controversial, so we aimed to provide robust information on the utility of 18FDG-PET in the diagnosis and management of BTC. Methods This systematic review and meta-analysis explored the diagnostic test accuracy of 18FDG-PET as a diagnostic tool for diagnosis of primary tumour, lymph node invasion, distant metastases and relapsed disease. Subgroup analysis by study quality and BTC subtype were performed. Changes in management based on 18FDG-PET and impact of maximum standardised uptake values (SUVmax) on prognosis were also assessed. A random effects model was used for meta-analyses. Results A total of 2,125 patients were included from 47 eligible studies. The sensitivity (Se) and specificity (Sp) of 18FDG-PET for the diagnosis of primary tumour were 91.7% (95% CI 89.8–93.2) and 51.3% (95% CI 46.4–56.2), respectively, with an area under the curve (AUC) of 0.8668. For lymph node invasion, Se was 88.4% (95% CI 82.6–92.8) and Sp was 69.1% (95% CI 63.8–74.1); AUC 0.8519. For distant metastases, Se was 85.4% (95% CI 79.5–90.2) and Sp was 89.7% (95% CI 86.0–92.7); AUC 0.9253. For relapse, Se was 90.1% (95% CI 84.4–94.3) and Sp was 83.5% (95% CI 74.4–90.4); AUC 0.9592. No diagnostic threshold effect was identified. Meta-regression did not identify significant sources of heterogeneity. Sensitivity analysis revealed no change in results when analyses were limited to studies with low risk of bias/concern. The pooled proportion of change in management was 15% (95% CI 11–20); the majority (78%) due to disease upstaging. Baseline high SUVmax was associated with worse survival (pooled hazard ratio of 1.79; 95% CI 1.37–2.33; p <0.001). Conclusions There is evidence to support the incorporation of 18FDG-PET into the current standard of care for the staging (lymph node and distant metastases) and identification of relapse in patients with BTC to guide treatment selection; especially if the identification of occult sites of disease would change management, or if diagnosis of relapse remains unclear following standard of care imaging. The role for diagnosis of the primary tumour remains controversial due to low sensitivity and 18FDG-PET should not be considered as a replacement for pathological confirmation in this setting. Lay summary A positron emission tomography (PET scan), using 18F-fluorodeoxyglucose (18FDG), can help doctors identify areas of cancer in the body by highlighting “hot spots”. These hotspots may be cancerous (true positive) but may also be non-cancerous, like inflammation (false positive). We show that PET scans are useful to assess how far advanced the cancer is (by assessing spread to lymph glands and to other organs) and also to identify if the cancer has recurred (for example after surgery), thus helping doctors to make treatment decisions. However, a biopsy is still needed for the initial diagnosis of a biliary tract cancer, because of the high chance of a “false positive” with PET scans. The role of 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and staging of patients with biliary tract cancers (BTCs) remains controversial, so we aimed to provide robust information on the utility of 18FDG-PET in the diagnosis and management of BTC. This systematic review and meta-analysis explored the diagnostic test accuracy of 18FDG-PET as a diagnostic tool for diagnosis of primary tumour, lymph node invasion, distant metastases and relapsed disease. Subgroup analysis by study quality and BTC subtype were performed. Changes in management based on 18FDG-PET and impact of maximum standardised uptake values (SUVmax) on prognosis were also assessed. A random effects model was used for meta-analyses. A total of 2,125 patients were included from 47 eligible studies. The sensitivity (Se) and specificity (Sp) of 18FDG-PET for the diagnosis of primary tumour were 91.7% (95% CI 89.8–93.2) and 51.3% (95% CI 46.4–56.2), respectively, with an area under the curve (AUC) of 0.8668. For lymph node invasion, Se was 88.4% (95% CI 82.6–92.8) and Sp was 69.1% (95% CI 63.8–74.1); AUC 0.8519. For distant metastases, Se was 85.4% (95% CI 79.5–90.2) and Sp was 89.7% (95% CI 86.0–92.7); AUC 0.9253. For relapse, Se was 90.1% (95% CI 84.4–94.3) and Sp was 83.5% (95% CI 74.4–90.4); AUC 0.9592. No diagnostic threshold effect was identified. Meta-regression did not identify significant sources of heterogeneity. Sensitivity analysis revealed no change in results when analyses were limited to studies with low risk of bias/concern. The pooled proportion of change in management was 15% (95% CI 11–20); the majority (78%) due to disease upstaging. Baseline high SUVmax was associated with worse survival (pooled hazard ratio of 1.79; 95% CI 1.37–2.33; p <0.001). There is evidence to support the incorporation of 18FDG-PET into the current standard of care for the staging (lymph node and distant metastases) and identification of relapse in patients with BTC to guide treatment selection; especially if the identification of occult sites of disease would change management, or if diagnosis of relapse remains unclear following standard of care imaging. The role for diagnosis of the primary tumour remains controversial due to low sensitivity and 18FDG-PET should not be considered as a replacement for pathological confirmation in this setting." @default.
W2917063498 created "2019-03-02" @default.
W2917063498 creator A5003454059 @default.
W2917063498 creator A5006284946 @default.
W2917063498 creator A5027556665 @default.
W2917063498 creator A5041768679 @default.
W2917063498 creator A5060729173 @default.
W2917063498 creator A5067220984 @default.
W2917063498 creator A5075059160 @default.
W2917063498 creator A5087850177 @default.
W2917063498 date "2019-07-01" @default.
W2917063498 modified "2023-10-12" @default.
W2917063498 title "18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis" @default.
W2917063498 cites W1480384227 @default.
W2917063498 cites W1529435536 @default.
W2917063498 cites W1760664724 @default.
W2917063498 cites W1894932324 @default.
W2917063498 cites W1965716049 @default.
W2917063498 cites W1968648271 @default.
W2917063498 cites W1973967338 @default.
W2917063498 cites W1976713834 @default.
W2917063498 cites W1981217896 @default.
W2917063498 cites W1982286537 @default.
W2917063498 cites W1982695492 @default.
W2917063498 cites W1987801163 @default.
W2917063498 cites W1988713337 @default.
W2917063498 cites W1990473526 @default.
W2917063498 cites W1994875712 @default.
W2917063498 cites W1995548432 @default.
W2917063498 cites W1996809999 @default.
W2917063498 cites W1997566313 @default.
W2917063498 cites W1998737374 @default.
W2917063498 cites W1999241037 @default.
W2917063498 cites W1999657893 @default.
W2917063498 cites W2008716434 @default.
W2917063498 cites W2018907156 @default.
W2917063498 cites W2019661425 @default.
W2917063498 cites W2022340989 @default.
W2917063498 cites W2023989329 @default.
W2917063498 cites W2028584595 @default.
W2917063498 cites W2031418261 @default.
W2917063498 cites W2039966280 @default.
W2917063498 cites W2042863595 @default.
W2917063498 cites W2044013897 @default.
W2917063498 cites W2048133408 @default.
W2917063498 cites W2052090600 @default.
W2917063498 cites W2053815151 @default.
W2917063498 cites W2055380023 @default.
W2917063498 cites W2057084620 @default.
W2917063498 cites W2059602499 @default.
W2917063498 cites W2063386799 @default.
W2917063498 cites W2063597348 @default.
W2917063498 cites W2064434671 @default.
W2917063498 cites W2064606534 @default.
W2917063498 cites W2069274689 @default.
W2917063498 cites W2071599705 @default.
W2917063498 cites W2073376274 @default.
W2917063498 cites W2075660225 @default.
W2917063498 cites W2078797029 @default.
W2917063498 cites W2079329255 @default.
W2917063498 cites W2079892049 @default.
W2917063498 cites W2080587420 @default.
W2917063498 cites W2087155126 @default.
W2917063498 cites W2090663452 @default.
W2917063498 cites W2092072739 @default.
W2917063498 cites W2092923243 @default.
W2917063498 cites W2094475323 @default.
W2917063498 cites W2098442347 @default.
W2917063498 cites W2100280977 @default.
W2917063498 cites W2106550415 @default.
W2917063498 cites W2106716706 @default.
W2917063498 cites W2107328434 @default.
W2917063498 cites W2107638293 @default.
W2917063498 cites W2110487507 @default.
W2917063498 cites W2115261608 @default.
W2917063498 cites W2115464537 @default.
W2917063498 cites W2116308061 @default.
W2917063498 cites W2119605658 @default.
W2917063498 cites W2121100008 @default.
W2917063498 cites W2122960876 @default.
W2917063498 cites W2124609632 @default.
W2917063498 cites W2125435699 @default.
W2917063498 cites W2129650248 @default.
W2917063498 cites W2134023012 @default.
W2917063498 cites W2136264959 @default.
W2917063498 cites W2137816907 @default.
W2917063498 cites W2138385272 @default.
W2917063498 cites W2139129657 @default.
W2917063498 cites W2148899606 @default.
W2917063498 cites W2151047141 @default.
W2917063498 cites W2157573823 @default.
W2917063498 cites W2157823046 @default.
W2917063498 cites W2159772495 @default.
W2917063498 cites W2160223999 @default.
W2917063498 cites W2169160087 @default.
W2917063498 cites W2170065216 @default.
W2917063498 cites W2204134524 @default.
W2917063498 cites W2280171286 @default.